Michael Schmidt
Stock Analyst at Guggenheim
(3.37)
# 869
Out of 4,826 analysts
106
Total ratings
52.56%
Success rate
0.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $32 | $12.14 | +163.59% | 3 | May 6, 2025 | |
| ARVN Arvinas | Maintains: Buy | $32 → $16 | $7.46 | +114.48% | 5 | May 2, 2025 | |
| SWTX SpringWorks Therapeutics | Downgrades: Neutral | $77 → $47 | $46.24 | +1.64% | 2 | Apr 29, 2025 | |
| CMPX Compass Therapeutics | Reiterates: Buy | n/a | $1.75 | - | 3 | Apr 22, 2025 | |
| ONC BeiGene | Reiterates: Buy | n/a | $251.00 | - | 2 | Apr 16, 2025 | |
| NBTX Nanobiotix | Maintains: Buy | $12 → $8 | $3.54 | +125.99% | 2 | Apr 4, 2025 | |
| ADCT ADC Therapeutics | Maintains: Buy | $10 → $7 | $1.30 | +438.46% | 4 | Mar 31, 2025 | |
| MRUS Merus | Reiterates: Buy | $109 | $42.17 | +158.48% | 5 | Mar 28, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | $3 → $1.75 | $0.30 | +476.61% | 3 | Mar 26, 2025 | |
| VSTM Verastem | Maintains: Buy | $13 → $14 | $6.92 | +102.31% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $25 | $8.26 | +202.66% | 2 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $92 | $61.34 | +49.98% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $32.53 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $20.83 | +116.03% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $5.30 | - | 5 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $38.64 | +8.70% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.55 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $101.56 | - | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $3.37 | +493.47% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $87 | $39.29 | +121.43% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.28 | +525.00% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $30.44 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.37 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.26 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $0.32 | +2,083.41% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.59 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $10.17 | +234.32% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $0.64 | +3,028.91% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $21.12 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.37 | +1,724.82% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $4.45 | +574.16% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $3.70 | +602.70% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.62 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.84 | - | 4 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $29.68 | +169.59% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.25 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.44 | +60.12% | 2 | Nov 7, 2017 |
Syndax Pharmaceuticals
May 6, 2025
Reiterates: Buy
Price Target: $32
Current: $12.14
Upside: +163.59%
Arvinas
May 2, 2025
Maintains: Buy
Price Target: $32 → $16
Current: $7.46
Upside: +114.48%
SpringWorks Therapeutics
Apr 29, 2025
Downgrades: Neutral
Price Target: $77 → $47
Current: $46.24
Upside: +1.64%
Compass Therapeutics
Apr 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $1.75
Upside: -
BeiGene
Apr 16, 2025
Reiterates: Buy
Price Target: n/a
Current: $251.00
Upside: -
Nanobiotix
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $3.54
Upside: +125.99%
ADC Therapeutics
Mar 31, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.30
Upside: +438.46%
Merus
Mar 28, 2025
Reiterates: Buy
Price Target: $109
Current: $42.17
Upside: +158.48%
Adaptimmune Therapeutics
Mar 26, 2025
Maintains: Buy
Price Target: $3 → $1.75
Current: $0.30
Upside: +476.61%
Verastem
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $6.92
Upside: +102.31%
Mar 20, 2025
Maintains: Buy
Price Target: $35 → $25
Current: $8.26
Upside: +202.66%
Mar 18, 2025
Downgrades: Neutral
Price Target: $92
Current: $61.34
Upside: +49.98%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $32.53
Upside: -
Mar 10, 2025
Initiates: Buy
Price Target: $45
Current: $20.83
Upside: +116.03%
Feb 26, 2025
Reiterates: Buy
Price Target: n/a
Current: $5.30
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $38.64
Upside: +8.70%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.55
Upside: -
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $101.56
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $3.37
Upside: +493.47%
Dec 3, 2024
Maintains: Buy
Price Target: $82 → $87
Current: $39.29
Upside: +121.43%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.28
Upside: +525.00%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $30.44
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.37
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.26
Upside: -
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $0.32
Upside: +2,083.41%
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $10.17
Upside: +234.32%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $0.64
Upside: +3,028.91%
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $21.12
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $1.37
Upside: +1,724.82%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $4.45
Upside: +574.16%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $3.70
Upside: +602.70%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.62
Upside: -
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $3.84
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $29.68
Upside: +169.59%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $5.25
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.44
Upside: +60.12%